The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents

Gerlinde Karbon1, Manuel D. Haschka1, Hubert Hackl2, Claudia Soratroi1, Lourdes Rocamora-Reverte1,5, Walther Parson3, Heidelinde Fieg14 and Andreas Villunger15

© The Author(s) 2021

Breast cancer (BC) treatment frequently involves microtubule-targeting agents (MTAs), such as paclitaxel, that arrest cells in mitosis. Sensitivity to MTAs is defined by a subset of pro- and anti-apoptotic BCL2 family proteins controlling mitochondrial apoptosis. Here, we aimed to determine their prognostic value in primary tumour samples from 92 BC patients. Our analysis identified high NOXA/PAIP mRNA expression levels as an independent prognostic marker for improved relapse-free survival (RFS) and overall survival (OS) in multivariate analysis in BC patients, independent of their molecular subtype. Analysis of available TCGA datasets of 1060 BC patients confirmed our results and added a clear predictive value of NOXA mRNA levels for patients who received MTA-based therapy. In this TCGA cohort, 122 patients received MTA-treatment and high NOXA mRNA levels correlated with their progression-free interval (PFI) and OS. Our follow-up analyses in a panel of BC cell lines of different molecular subtypes identified NOXA protein expression as a key determinant of paclitaxel sensitivity in triple-negative breast cancer (TNBC) cells. Moreover, we noted highest additive effects between paclitaxel and chemical inhibition of BCLX, but not BCL2 or MCL1, documenting dependence of TNBC cells on BCLX for survival and paclitaxel sensitivity defined by NOXA expression levels.

Cell Death and Disease (2021) 12:1151; https://doi.org/10.1038/s41419-021-04415-y

INTRODUCTION

Breast cancer (BC) is with 13.3% the most common type of cancer in women [1]. BC can be classified into three main subfamilies according to the presence or absence of the hormone receptors for oestrogen (ER) and progesterone (PR) and the human epidermal growth factor receptor 2 (HER2) status: Luminal A/B (about 40%, ER+/PR+/HER2-), HER2+ (10-15%, ER-/PR+/HER2+) and those negative for all these markers, referred to as TNBC (15-20%, ER-/PR-/HER2-). TNBC therapy involves aggressive chemotherapies those negative for all these marker, referred to as TNBC (15-20%, ER-/PR-/HER2-). TNBC therapy involves aggressive chemotherapies due to lack of clear molecular targets [2, 3]. PARP1 inhibitors, Olaparib and Talazobarb, and the immune checkpoint inhibitor Atezolizumab, targeting PD-L1, in combination with the microtubule targeting agent (MTA) paclitaxel are novel treatment strategies used, reviewed by Lyons [4].

MTAs, like vincristine or paclitaxel, inhibit microtubule dynamics [5]. This eventually activates the spindle assembly checkpoint (SAC) and triggers mitotic (M)-arrest when applied in tissue culture, eventually leading to apoptosis [6]. Paclitaxel shows success in treating metastatic breast and ovarian cancer, as well as various leukaemias [5, 7]. Although MTAs are largely successful, resistance and neurotoxicity limit their broader application [8]. One way to evade mitotic cell death (MCD) is to overexpress anti-apoptotic BCL2 proteins [9]. In BC, MCL1, BCL2 and BCLX are often found amplified [10, 11], making them more resistant to different types of therapeutics [12, 13], including paclitaxel [14]. MCD is a desired outcome in cancer therapy, yet clinical efficacy also involves alternative anti-proliferative and pro-inflammatory effects [15]. Of note, tumour cells often manage to escape cell death in a process called "mitotic slippage", the premature exit from mitosis, triggered by the gradual decay of cyclin B levels below a critical threshold, allowing cell survival [16, 17].

We and others recently demonstrated that the molecular mechanism underlying MCD depends on the activity of BH3-only proteins, most notably BIM and NOXA, and the degradation of anti-apoptotic MCL1 [18]. We could further demonstrate that NOXA protein mediates the degradation of MCL1 during extended M-arrest and that knockdown of NOXA leads to MCL1 stabilisation and resistance to MTAs in HeLa cervical cancer and A549 lung cancer cells [18]. In a follow-up study, we reported that the co-degradation of NOXA/MCL1 complexes during extended M-arrest requires the mitochondrial E3-ligase MARCH5 [19], suggesting that its inhibition may help increase the efficacy of MTAs. Interestingly, ablation of the mitochondrial GTPase DRP1, deregulating mitochondrial network dynamics, sensitizes epithelial cancer cells to MTA-induced apoptosis [20]. Taken together, this places mitochondria at the core of mitotic cell death regulation and MTA treatment success.

1Institute for Developmental Immunology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria. 2Institute for Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria. 3Institute of Legal Medicine, Medical University Innsbruck, Innsbruck, Austria. 4Department for Obstetrics & Gynecology, Medical University of Innsbruck, Innsbruck, Austria. 5Present address: Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, Austria. Email: andreas.villunger@i-med.ac.at

Received: 2 June 2021 Revised: 11 November 2021 Accepted: 22 November 2021
Published online: 13 December 2021
ABT-199 (Venetoclax), solely targeting BCL2 within the sub-nanomolar-range, shows clinical efficacy in CLL [24], is heavily explored in clinical trials and shows promising results in ER$^+$ BC patient-derived xenotransplants (PDX) [25]. Wehi-539 and its successors, A-1155463 and A-1331852, are targeting BCLX within sub-nanomolar-range [26] but cause thrombocytopenia, limiting clinical application [27, 28]. More recently, a highly specific MCL1 inhibitor, S63845, was shown to have potent anti-tumour activity as a single-agent in preclinical leukaemia models [29], as well as in combination with ABT-199 in BC PDX studies [30].

Here, we tested the predictive value of BCL2 family expression levels for BC patient survival in a patient cohort with detailed clinical follow-up and investigated the biological significance of the NOXA/MCL1 axis for MCD in BC cell lines exposed to paclitaxel and BH3 mimetics.

RESULTS

High NOXA/PMAIP mRNA expression predicts superior survival of BC patients receiving MTA-based therapy

We investigated the mRNA expression of pro-apoptotic effectors (BAX, BAK, BOK), BH3-only proteins previously involved in MTA-induced cell death (BID, BIM, PUMA, NOXA) and anti-apoptotic BCL2 family members (MCL1, BCL2, BCLX, BCLW, BCLB) within fresh-frozen tissue samples of different molecular subtypes from 92 patients with primary BC. Our first analysis revealed significant differences in relative mRNA levels between healthy and diseased tissue for anti-apoptotic BCL2, BCLX/BCL2L1 and MCL1. Of note, BCL2 expression was significantly lower in cancerous tissue (Fig. 1A), while BCLX and MCL1 levels were found increased (Fig. 1B). Analysis of their pro-apoptotic counterparts, the BH3-only proteins BID and NOXA, revealed a significant increase in mRNA levels in cancers compared to non-neoplastic tissue (Fig. 1B). In contrast, PUMA and BIM/BCL2L11 levels and the effector proteins BAX, BAK or BOK or the anti-apoptotic proteins BCLW and BCLB were comparable (Fig. 1C). Pearson correlation analyses revealed significant associations for the co-expression of MCL1 with PUMA or BAX, as well as BCLW/BCL2L2 with PUMA or BAX. Amongst the pro-death proteins, an interdependence was noted between BAX and BOK or the BH3-only protein PUMA or BID with BAX (Suppl. Fig. 1A), suggesting co-regulation of gene expression.

When analysing clinical parameters, we confirmed previous findings [25] by documenting high BCL2 mRNA expression in low-grade and luminal A type BC patients still expressing HR (Suppl. Table 1). Consistent with BCL2 being a target of HR signalling, levels were generally higher in HR$^+$ tumours (Suppl. Table 1). BCLX expression correlated with the same parameters and was enriched in HER2$^+$ tumours but no longer associated with low tumour grade. Neither MCL1 nor BCLW mRNA showed any correlation with clinical parameters, but BCLW showed higher expression in large tumours. Amongst the pro-apoptotic genes, expression of BID associated with high tumour grade while NOXA was found higher expressed in medullary carcinomas (Suppl. Table 1).

Performing ROC analyses to define the best cut-off to identify significant patient survival differences across cancer subtypes revealed a clear correlation between higher BCL2 expression levels and a superior RFS. Higher levels of MCL1 correlated significantly with a good OS in univariate analyses (Table 1). Of note, NOXA and BOK expression showed a strong correlation with both RFS and OS. While high NOXA expression was associated with superior survival, strong BOK expression was associated with poor survival (Table 1). Importantly, this correlation pattern for BOK and NOXA was maintained when multivariate analyses were performed (Table 2). Expression of BCL2 still correlated with RFS, while levels of MCL1 correlated only with improved OS (Table 2). Notably, these correlations were verified by analysing the TCGA database containing expression data of 1060 BC patients; from those, 471 patients were treated with chemotherapy, from which 112 patients received MTAs (Fig. 2A–D). Strikingly, NOXA mRNA

Along this line, BH3 mimetics, inhibiting anti-apoptotic BCL2 proteins, are confirmed to be sufficient to prime cancer cells to various chemotherapeutics, including paclitaxel [21]. BH3-mimetics bypass the need for upstream inducers of BH3-only proteins, such as p53 or PTEN, which are frequently impaired in human cancers. The first valid prototype of a BH3-mimetic, ABT-737, targeting BCL2, BCLX and BCLW, showed promising efficacy in haematological malignancies [22]. However, several cancer types are resistant to ABT-737, or its orally bioavailable successor, Navitoclax (ABT-263), due to the overexpression of MCL1 [23].

Fig. 1 mRNA expression analysis of BCL2 family members in 10 non neoplastic and 92 neoplastic breast tissues. mRNA expression of A BCL2 ($p = 0.039$), B BCLX ($p = 0.035$), MCL1 ($p = 0.001$), BID ($p = 0.020$) and NOXA ($p = 0.002$) and C PUMA, BIM, BAX, BAK, BOK, BCLW and BCLB. Extreme values are marked with asterisks, outliers with circles.
expression levels correlated with OS and PFI within BC patients from the TCGA dataset treated with MTA but no other type of chemotherapy (Fig. 2E, F), showing its relevance and confirming the predictive value of our data (Table 2). Selected patient samples were also tested for NOXA protein levels, confirming a correlation between mRNA and protein levels (Suppl. Fig. 1B). Within the TCGA validation cohort, however, BOK expression levels no longer correlated with survival (data not shown).

| Variable                        | Relapse-free survival | Overall survival |
|--------------------------------|-----------------------|------------------|
|                                | Median, years (95% CI)| P-value (logrank-test) | Median, years (95% CI)| P-value (logrank-test) |
| Size                           | T1                    | n.r.              | 0.150               | n.r.              | 0.093   |
|                                | T2/3/4                | 8.09 (0.00–19.35) | 10.44 (4.62–16.25) | 0.007             |
| LN                             | Negative              | n.r.              | 0.112               | n.r.              | 0.0007  |
|                                | Positive              | n.r.              | 9.93 (6.35–13.50)  | 0.886             |
| Tumour grade                   | I                     | n.r.              | 0.609               | 10.73 (8.69–12.78) | 0.867   |
|                                | II                    | 8.09 (n.r.)       | 14.64 (8.81–20.47) | 0.905             |
|                                | III                   | n.r.              | 16.91 (8.76–20.06) |                  |
| Histology                      | invasive lobular      | n.r.              | 0.187               | 18.69 (5.86–31.53) | 0.001   |
|                                | breast cancer         |                   |                     |                   |
|                                | invasive ductal       | 8.09 (0.00–17.91) | 12.15 (6.51–17.79) | 0.010             |
|                                | breast cancer         |                   |                     |                   |
|                                | medullary breast      | n.r.              | 16.91 (5.20–28.62) | 0.001             |
|                                | cancer                |                   |                     |                   |
| MP                             | premenopausal         | 8.09 (0.00–19.69) | 0.492               | n.r.              | 0.106   |
|                                | postmenopausal        | n.r.              | 10.73 (5.33–16.14) | 0.067             |
| HER2                           | neg                   | n.r.              | 0.127               | 16.91 (12.90–20.92) | 0.870   |
|                                | pos                   | 5.23 (3.85–6.62)  | 7.25 (3.22–11.28)  | 0.696             |
| ER                             | neg                   | n.r.              | 0.646               | 16.91 (5.01–28.81) | 0.905   |
|                                | pos                   | 19.23 (2.81–35.65)| 14.64 (8.94–20.35) | 0.376             |
| PR                             | neg                   | n.r.              | 0.709               | 10.20 (0.00–22.45) | 0.617   |
|                                | pos                   | 19.23 (3.15–35.32)| 14.64 (9.48–19.80) | 0.014             |
| MTA chemotherapy               | no                    | 5.95 (0.00–16.78) | 0.057               | 8.76 (6.60–10.92) | 0.001   |
|                                | yes                   | n.r.              | 10.73 (5.33–16.14) | 0.017             |
| Radiation therapy              | no                    | n.r.              | 0.316               | 16.91 (12.90–20.92) | 0.870   |
|                                | yes                   | 6.77 (0.00–17.27) | 17.78 (9.74–25.83) | 0.617             |
| Endocrine therapy              | no                    | n.r.              | 0.658               | 14.64 (4.38–24.90) | 0.601   |
|                                | yes                   | n.r.              | 12.15 (6.23–18.07) | 0.014             |
| BCL2 mRNA expression           | low (<48th percentile)| 4.72 (2.07–7.36)  | **0.003**           | 8.59 (2.04–15.14) | 0.017   |
|                                | high (>48th percentile)| n.r.              |                     | 15.46 (7.41–23.52) | 0.014   |
| MCL1 mRNA expression           | low (<53rd percentile)| 5.95 (n.r.)       | 0.128               | 9.35 (7.11–11.59) | 0.001   |
|                                | high (>53rd percentile)| 19.23 (n.r.)     | 17.95 (n.r.)        |                  |
| NOXA mRNA expression           | low (<12th percentile)| 1.98 (1.44–2.52)  | **<0.001**          | 3.28 (1.64–4.92)  | **<0.001** |
|                                | high (>12th percentile)| n.r.              | 16.91 (13.39–20.43) | 0.010             |
| BOK mRNA expression            | low (<34th percentile)| n.r.              | **0.008**           | n.r.              | 0.001   |
|                                | high (>34th percentile)| 5.95 (2.70–9.20) | 10.44 (6.92–13.96) | 0.010             |

Note: The significance level (P) was determined by log-rank test.

Table 1. Univariate survival analysis of relapse free and overall survival of 92 patients with primary breast cancer diagnosed and treated at the Medical University of Innsbruck, AT.

**expression levels correlated with OS and PFI within BC patients from the TCGA dataset treated with MTA but no other type of chemotherapy (Fig. 2E, F), showing its relevance and confirming the predictive value of our data (Table 2). Selected patient samples were also tested for NOXA protein levels, confirming a correlation between mRNA and protein levels (Suppl. Fig. 1B). Within the TCGA validation cohort, however, BOK expression levels no longer correlated with survival (data not shown).**

**NOXA protein expression defines MTA-sensitivity in TNBC cell lines**

We further investigated the expression profile of NOXA and its relevance for MTA-treatment in relation to other members of the BCL2 protein family in more detail. Therefore, we chose eight different BC cell lines, representing the three main subfamilies: Luminal A/B (MCF-7, T47D and ZR-75-1), TNBC (HS-578-T, MDA-MB-231, Cal-51 and BT20) and HER2+ (SKBR3) and analysed protein expression levels of the most common pro- and anti-apoptotic proteins. The expression of BCL2, NOXA, BIM, BCLB and BOK differed substantially amongst cell lines, whereas MCL1, BCLX, or BID expression levels show less variability (Fig. 3A, B). The protein expression of NOXA was highest in the TNBC cell lines, while BOK was hardly detectable in this subset. MDA-MB-231, HS-578-T and T47D also showed a slightly higher expression of BCLX than the other BC cell lines (Fig. 3A), suggesting co-dependence on BCLX.
for survival. The strong expression of different BCL2 pro-survival proteins suggests variable dependency for cell survival that does not correlate with a particular molecular subtype, which we investigated in the next step using selective BH3 mimetics.

BH3-mimetics efficiently enhance the effects of paclitaxel

All cell lines were treated either with fixed concentrations of paclitaxel alone or in combination with a graded concentration of the different BH3 mimetics, including ABT-737, ABT-199, S63845 and Wehi-539 (Suppl. Fig. 2), or vice versa (Suppl. Fig. 3). MTT-assay was used as an indirect readout for cell viability. As expected, the cell lines showed different sensitivity against paclitaxel which did not correlate with a particular molecular subtype. Two of the TNBC cell lines, Cal-51 and BT20, were most sensitive to MTA-treatment. Their metabolic activity dropped to about 31% and 25%, respectively, when treated with paclitaxel alone (Fig. 4A). In contrast, the ER+ cell lines ZR-75-1 (83%), T47D (58%) and MCF-7 (50%) showed reduced MTA-sensitivity (Fig. 4A).

A saturation using 50 nM paclitaxel was visible for all cell lines tested. Higher concentrations did not reduce metabolic activity any further, with the notable exception of the HS-578-T cells (Suppl. Fig. 3).

Inhibiting the pro-survival BCL2 proteins with the different BH3 mimetics alone was mostly ineffective. The BCL2 inhibitor ABT-199 did not affect any cell line at the assayed concentrations (up to 5 µM), including MCF7 cells, which showed the highest BCL2 expression. Similar, the MCL1 inhibitor S63845 only affected MCF-7 and SKBR3 cell lines (Suppl. Fig. 2). However, ABT-737, inhibiting BCL2, BCLX and BCLW, and the BCLX inhibitor, Wehi-539, showed activity in some cell lines when used at high doses as a single agent (Fig. 4B). Notably, combining paclitaxel with BH3 mimetics led to additive effects, despite variations in their overall potency (Fig. 4, Suppl. Figs. 2, 4, 5). In combination with the MCL1 inhibitor S63845, paclitaxel most potently reduced the metabolic activity of MCF7 cells from 50% (paclitaxel) to 22% (paclitaxel + S63845; Fig. 4A). The combination of paclitaxel with the BCL2 inhibitor ABT-199 had only a mild effect on HS-578-T or MCF-7 cells despite their high BCL2 levels (Fig. 4A, Suppl. Figs. 2, 4, 5).

Potent effects on all cell lines tested were consistently seen when paclitaxel was combined with ABT-737, having the most substantial impact on the TNBC cell lines HS-578-T and MDA-MB-231. Their metabolic activity was further reduced on average by 27% and 25%, respectively, in the combination setting (Fig. 4A). This finding points towards a critical role for BCLX for cell survival after paclitaxel treatment. Consistently, the most pronounced effects were seen using paclitaxel together with the selective BCLX inhibitor, Wehi-539. This inhibitor further decreased metabolic activity by 33% and 49% in the HS-578-T and MDA-MB-231, respectively (Fig. 4). An increase of the paclitaxel concentration to 500 nM combined with Wehi-539 eliminated all viable MDA-MB-231 cells (Suppl. Fig. 3A).

To optimise the effect between paclitaxel and BH3 mimetics, we chose the estimated LD50 concentration of paclitaxel and titrated the different BH3 mimetics. Only inhibition of BCLX, by using ABT-737 or Wehi-539, showed effects as single agents at the highest drug concentration used, i.e., 5 µM. (Fig. 4B–E, Suppl. Figs. 2, 4, 5). An additive effect was best seen in the TNBC cell lines, identifying BCLX as their primary survival factor that, together with the NOXA/MCL1 axis, may define responsiveness to MTAs.

The NOXA/MCL1 axis controls paclitaxel-induced cell death in TNBC cell lines

We could previously show that NOXA driven degradation of MCL1 during extended M-arrest promotes cell death [18]. This may explain why chemical inhibition of MCL1 had little effect on paclitaxel sensitivity, as it is automatically degraded upon paclitaxel treatment. We chose the TNBC cell lines HS-578-T, MDA-MB-231 and Cal-51 to analyse the relevance of the NOXA/MCL1 axis for MCD as they showed the strongest NOXA expression. Of note, while MCL1 levels were comparable in these cell lines, NOXA expression appears graded, with the MDA-MB-231 cell line having the highest, followed by HS-578-T and the Cal-51 showing the lowest NOXA levels (Fig. 3).

All three cell lines were synchronised with a double-thymidine arrest and released into paclitaxel-containing media to induce prolonged M-arrest. Mitotic shock off was used to enrich cells arrested in mitosis. CDK1-mediated phosphorylation of CDC27 in mitosis, a component of the anaphase-promoting complex (APC), validated the synchronisation procedure (Fig. 5). We observed that MCL1 and NOXA are co-degraded during extended M-arrest in all three TNBC cell lines. Overall, the NOXA levels followed MCL1 expression and peaked in G2/M before being co-degraded (Fig. 5).

The reduction of MCL1/NOXA levels correlated well with apoptosis onset, as monitored by caspase-mediated cleavage of PARP1. Cal-51 cells showed the strongest PARP1 cleavage during extended M-arrest, followed by HS-578-T cells. In strong contrast,
MDA-MB-231 cells showed no detectable PARP1 cleavage, indicating resistance against paclitaxel (Fig. 5A). These patterns fit the observed paclitaxel sensitivity/resistance phenotypes noted in the MTT-assays presented above (Fig. 4A, Suppl. Fig. 3F).

All three cell lines showed the described phosphorylation of BIM in mitosis, which promotes its APCCDC20-driven degradation [18, 31]. BCLX and BCL2 are well known to be phosphorylated during mitosis [9, 32–34]; this was best observed for BCLX, most of it migrating significantly slower in SDS-PAGE, less notable for BCL2, at least with the antibody used (Fig. 5).

To assess the relevance of NOXA/MCL1 turnover for tumour cell survival, we generated NOXA-KO derivatives from these three TNBC cell lines using two independent sgRNAs targeting NOXA. While the steady-state levels of MCL1 did not substantially differ in asynchronous cells, we could observe a clear stabilisation of MCL1 in the absence of NOXA compared to parental cells upon extended M-arrest (Fig. 5). HS-578-T cells showed the most robust MCL1 stabilisation upon M-arrest, followed by the MDA-MB-231 cells, while this effect was modest in the Cal-51 cell line. Regardless, the absence of NOXA was beneficial for survival upon MTA-treatment, as PARP1 cleavage was strongly reduced in the HS-578-T (Fig. 5B) and the Cal-51 cells (Fig. 5C). As there was no PARP1 cleavage detectable in the parental MDA-MB-231 cells, no such effect was observed in NOXA-KO cell lines (Fig. 5A).
**NOXA promotes paclitaxel-induced cell death and synergy with BH3-mimetics**

Monitoring PARP1 cleavage by western blot may not have been sensitive enough to reveal a contribution of NOXA to paclitaxel-induced cell death, either when used alone or in combination with BH3-mimetics. Hence, to assess if NOXA-deficiency provides MDA-MB-231 cells with a potential survival benefit, we treated these cells with paclitaxel plus BH3-mimetics (Fig. 6). The metabolic activity was reduced in the parental cell line by 25%, remaining higher in the NOXA-KO clones (72% and 66%, respectively). This effect became more prominent when paclitaxel was combined with different BH3-mimetics (Fig. 6A, Suppl. Fig. 4A, Suppl. Fig. 5). Again, ABT-737 and Wehi-539 showed high mRNA levels of BCL2, BCLX, BCL, BAX, BAK, and BOK, implicated in endoplasmic reticulum stress induced apoptosis [35], also showed a highly significant prognostic value in uni- and multivariate analysis (Tables 1, 2), but not the TCGA data set. BOK has been implicated in Ca^{2+} signalling from the ER [36] and pyrimidine synthesis thereby affecting drug resistance and cell proliferation rates [37]. Yet, it remains unclear how low BOK expression would benefit BC patients. A more detailed analysis of this protein in BC appears warranted, in particular as loss of BOK reportedly prevents liver cancer in mice [38].

Looking at the predictive value of anti-apoptotic BCL2 proteins, we confirmed high mRNA levels of BCL2 as beneficial for RFS, as noted before [39, 40], and reconfirmed this within the TCGA dataset (Fig. 2A, B). A similar beneficial effect could be linked to MCL1 mRNA expression (Fig. 2C, D). It remains a matter of debate why high levels of a pro-survival protein may improve BC patients’ prognosis. Still, one can imagine a scenario where high BCL2 or MCL1 expression may reduce the pressure to delete other cell death regulators, such as p53, which comes at the price of impaired genomic stability [41]. In fact, BCL2 overexpression has been shown to delay tumour onset in animal models of irradiation-driven lymphoma and myelodysplastic syndrome transition into AML [42, 43]. MCL1 is a short-lived protein regulated mainly at the translational and post-translation level; hence, analysis of protein levels is critical. Consistently, studying a panel of tumour tissue specimens on a tissue microarray revealed that high expression of MCL1 predicts poor outcome in BC in all but the HER2 amplified subtype [44]. Consistent with these observations, a recent study reported the beneficial effects of chemical MCL1 inhibition and the MTA docetaxel in TNBC patient-derived xenotransplant (PDX) studies in mice [30].

Our characterisation of the BCL2 protein family expression in cell lines revealed high variation across subtypes (Fig. 3). The low expression of NOXA in SKBR3, T47D and ZR-75-1 (Fig. 3B) might indicate its downregulation as part of a selected survival mechanism. Resistance to therapy is frequently correlated with the downregulation of NOXA mRNA in multiple cancer types [45] and linked to the fact that NOXA plays a decisive role in the degradation of MCL1 [18, 46].

The TNBC MDA-MB-231 cell line showed an above-average resistance to paclitaxel, compared to the other two TNBC cell lines, which may be related to an increased propensity to undergo mitotic slippage [47, 48]. Low BAK levels were shown to increase resistance against paclitaxel [49], consistent with MCL1

---

**Fig. 3 BCL2 protein family expression in different BC cell lines.** Different BC cell lines were subjected to western blotting using the indicated antibodies recognising A anti- and B pro-apoptotic BCL-2 proteins. HSP90 was used as a loading control.
Fig. 4  Paclitaxel increases the sensitivity towards BH3 mimetics.  

A The indicated cell lines were treated with 50 nM paclitaxel alone or in combination with 1 µM of BH3mimetics for 48 h.  

B–E TNBC cell lines were treated with graded concentrations of BH3-mimetics in combination with a predetermined fixed concentration of paclitaxel for 48 h. Metabolic activity was calculated by setting the metabolic activity in relation to the DMSO control. Heatmaps show mean values of metabolic activity ranging from 0 to 100% as assessed by MTT-assay.  

A All cell lines (n = 3–4), B MDA-MB-231 (n = 6), C HS-578-T (n = 4), D Cal-51 (n = 6), E BT20 (n = 6).
indicated antibodies. Later, harvested cells were subjected to western analysis using the cells was reseeded and harvested 5 h (M)
were harvested in G2 and early M-phase (M); part of the M-phase with a double-thymidine block and released into 500 nM PTX. Cells
NOXA co-degradation. A
Cyclin B
pCDC27
CDC27
GAPDH

| A | MDA-MB-231 | MDA-MB-231 | MDA-MB-231 |
|---|------------|------------|------------|
|   | Parental   | NOXA-KO #1| NOXA-KO #2 |
| G2 | Asyn.      | G2         | G2         |
| M  | M + 5 h    | M + 5 h    | M + 10 h   |
| M  | M + 5 h    | M + 10 h   | M + 10 h   |

| B | HS-578-T | HS-578-T | HS-578-T |
|---|----------|----------|----------|
|   | Parental | NOXA-KO #1| NOXA-KO #2 |
| G2 | Asyn. | Asyn. | Asyn. |
| M  | G2 | M + 5 h | M + 5 h |
| M  | M + 10 h | M + 10 h | M + 10 h |

| C | Cal-51 | Cal-51 | Cal-51 |
|---|-------|-------|-------|
|   | Parental | NOXA-KO #1 | NOXA-KO #1 |
| G2 | Asyn. | Asyn. | Asyn. |
| M  | G2 | M + 5 h | M + 5 h |
| M  | M + 10 h | M + 10 h | M + 10 h |

Fig. 5 TNBC cell lines treated with paclitaxel show MCL1 and NOXA co-degradation. A–C TNBC proficient (Parental) or deficient in NOXA (NOXA-KO) were left asynchronous (Asyn.) or synchronised with a double-thymidine block and released into 500 nM PTX. Cells were harvested in G2 and early M-phase (M); part of the M-phase cells was reseeded and harvested 5 h (M + 5 h) and 10 h (M + 10 h) later. Harvested cells were subjected to western analysis using the indicated antibodies.

preferentially binding to BAK [46]. We could observe this for the ZR-75-1 and T47D cell line (Fig. 3B, Suppl. Fig. 3F, G). However, Cal-51 cells also showed a low BAK expression but are among the most paclitaxel-sensitive cell lines (Fig. 3B, Suppl. Fig. 3C), suggesting that BAK expression levels alone cannot be seen as a reliable predictor of paclitaxel sensitivity.

Similarly, the expression of BCL2 proteins among our BC cell lines did not allow predictions on their sensitivity against BH3-mimetics, best seen in MCF-7 cells when comparing BCL2 expression with sensitivity to ABT-199. Still, those cells were susceptible to inhibition of MCL1. This indicates that, despite frequent BCL2 upregulation, BCL2 is not a major survival protein for these tumour cells. However, an earlier study using ER+ PDX models could show that treating luminal BC with ABT-199 was as effective as ABT-737 combined with chemotherapy [25]. This suggests that BCL2 can become a critical survival factor when its co-expressed pro-survival partners are neutralised.

In a genome-wide siRNA screen, MCL1 was shown to be a critical survival factor in TNBC cells [50]. We used one of the latest MCL1 inhibitors in clinical development, S63845 [29]. However, it showed limited potency against TNBC cell lines when used as a single agent. Yet, the HER2+ SKBR3 were highly sensitive to S63845 alone, which correlates with the finding that these cells rely on MCL1 for survival [51]. While combining MCL1 inhibition with paclitaxel may be beneficial in some settings [30], our data show that BCLX seems to be generally more critical than MCL1 for BC survival (Fig. 4, Suppl. Fig. 2), in line with earlier observations [52]. BH3-profiling in MDA-MB-231 cells revealed its dependency on BCLX to antagonise pro-apoptotic function [53]. However, as a single agent, Wehi-539 was shown to have only a minor effect on the metabolic activity of TNBC, including the MDA-MB-231 [54], fitting our data. Nonetheless, combining Wehi-539 with MTAs in TNBC cell lines reveals a BCLX dependence (Fig. 5), suggesting higher therapy efficacy [55], probably triggered by IFN/IRF3-driven upregulation of NOXA [56]. PS3 regulated expression of NOXA seems to play a minor role in this setting, as MDA-MB231 and HS-578-T cells express only mutant p53. In line with these results, elevated levels of BCL2 and MCL1 can lead to resistance against Wehi-539 [26]. An improved version of Wehi-539, with oral activity, might allow the use of lower doses to avoid thrombocytopenia while still maintaining its anti-cancer efficacy [28]. In vivo studies of the BCLX inhibitor, A-1331852, already showed an enhancement of the effectiveness of paclitaxel [57], and new PROTAC-based concepts may facilitate clinical application avoiding thrombocytopenia [58, 59].

We could show that deleting NOXA leads to stabilisation of MCL1, giving TNBC a survival benefit during extended M- arrest (Fig. 5), in line with our previous studies in HeLa and A549 cells [18]. Stabilised MCL1 can bind BAK and/or sequester BIM, which otherwise would be free to activate the intrinsic apoptotic pathway [46, 60]. Upon NOXA dependent degradation of MCL1, more BIM is released from MCL1 sequestration and can execute apoptosis; this can be best seen in Cal-51 NOXA-KO cells (Fig. 5C), which show less protection against M-arrest when compared to MDA-MB-231 NOXA-KO cells. This might rely on the low NOXA expression per se, indicating that the NOXA/MCL1 axis might not be that prominent in this cell line or that these cells escape M-arrest by slippage [61]. The HS-578-T and MDA-MB-231 cell lines both showed a survival benefit upon NOXA deletion, as evident by the reduced parP1 cleavage in the NOXA-KO cells (Fig. 6, Suppl. Fig. 6).

In summary, the NOXA/MCL1 axis plays a crucial role in TNBC treated with MTAs. Therefore, it could be helpful to increase or restore NOXA expression by inhibiting its degradation, e.g. by targeting the E3 ligase function of MARCH5 (19). This would allow a dosage reduction of both MTAs and BCLX inhibitors, thereby avoiding their respective side effects of neurotoxicity and thrombocytopenia [58, 59].
Expression levels were quantified by reverse-transcription PCR in mRNA isolated from freshly frozen tumour and adjacent tissue from 92 patients with primary BC treated with chemotherapy after surgery (aged 30.3 to 86.7; median age at diagnosis, 53.0 years) and 10 patients with benign breast diseases (aged 19.8 to 46.0; median age at diagnosis, 35.5 years) treated at the Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Austria. Written informed consent is not available from all patients (specimen collections before the year 2000). But in accordance with the Austrian law, the study was reviewed and approved by the Ethics committee of the Medical University of Innsbruck (reference number: 1021/2017), it was conducted in accordance with the Declaration of Helsinki and in concordance with the Reporting Recommendations for Tumour Marker Prognostic Studies of the National Cancer Institute (REMARK) [62]. HR status was identified by immunohistochemistry (IHC). All samples were anonymized before analysis was performed, to guarantee the protection of privacy.

A power calculation for survival analysis was performed for BCL2 expression based on the univariate hazard ratio for mortality described by Dawson et al. (doi: 10.1038/sj.bjc.6605736) using the sample-size formula for the proportional-hazards regression model. The calculated, required total number of events was 16 (in our cohort 46 patients died, 41 had a relapse).

We analysed the BC dataset from The Cancer Genome Atlas (TCGA) project (n = 1060) described in [63, 64] including OS, DSS data and gene expression data from 471 resected primary breast tumours from patients treated with chemotherapy (aged 26.0 to 84.0 years; median age at diagnosis, 53.0 years).

**RNA isolation and reverse transcription for qRT-PCR**
Total cellular RNA extraction, reverse transcription and PCR reactions were performed as previously described [65]. Primers and probe for the TATA box-binding protein (TBP; endogenous RNA-control) were used according to Bieche et al. [66]. Primerlist can be found in the Suppl. Material Table 3.

**Tissue culture and generation of NOXA KO lines**
Cells were cultured in a humidified atmosphere containing 5% CO₂ at 37 °C with the required media (Suppl. Material Table 1) and routinely checked for mycoplasma. Amplification of 15 STR and amelogenin loci was carried out in the Institute of Legal Medicine, Innsbruck Medical University [67] for

![Fig. 6 NOXA deletion protects TNBC from PTX and BH3-mimetic co-treatment.](image-url)
fingerprinting the cell lines in use. Synchronisation with double-thymidine-arrest and generation of NOXA-KO (with CRISPR/Cas9 system) cells was performed as described previously [19]; guide sequences are found in Suppl. Material Table 3.

**Metabolic activity assessment**

Metabolic activity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay (Cell Proliferation Kit I, Roche Germany, Mannheim) according to manufacturer’s protocol. Cells were seeded in duplicates in 96-well flat-bottom plates and treated 24 h later with paclitaxel and/or graded doses of BH3-mimetics. DMSO was used as solvent control. Absorbance was measured at 570 nm and 650 nm using an ELISA plate reader (Sunrise, TECAN) with Magellan software (TECAN, V6.4). Metabolic activity was calculated in Excel, setting the OD-read of DMSO as solvent control. Absorbance was measured at 570 nm and 650 nm using an ELISA plate reader (Sunrise, TECAN) with Magellan software (TECAN, V6.4).

**Cell lysis and immunoblot analysis**

Cell lysis and immunoblot analysis was performed using SPSS statistical software (version 26.0; SPSS Inc.) and performed as described previously [19]; guide sequences are found in Suppl. Material Table 2.

**Statistical analysis**

Mann–Whitney U test was applied to compare mRNA expression levels between groups. Univariate Kaplan-Meier analyses and multivariate Cox survival analyses were used to explore the association of BCL2 family members mRNA expression levels with survival. Optimal thresholds for survival analyses were identified using Youden’s index [68] based on a receiver operating characteristic (ROC) curve analysis; analyses were performed using SPSS statistical software (version 26.0; SPSS Inc.).

One-tailed paired Student t-test was calculated on Prism8 (GraphPad Software) for Suppl. Fig. 3. Data in Suppl. Fig. 3 are represented with standard errors of the mean (SEM). Statistical significance is shown with symbols: \( p < 0.05 \), **\( p < 0.01 \) and ***\( p < 0.001 \).

**DATA AVAILABILITY**

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

**REFERENCES**

1. European Commission. 2020 Cancer incidence and mortality in EU-27 countries. 2020 [https://ec.europa.eu/jrc/en/news/2020-cancer-incidence-and-mortality-eu-27-countries].
2. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: molecular pro.

...Continued...

14. Real PJ, Sierra A, De, Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002;21:7611–8.
15. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–81.
16. Haschka M, Karbon G, Fava LL, Villunger A. Perturbing mitosis for anti-cancer therapy: is cell death the only answer? EMBO Rep. 2018;19:3.
17. Gascogne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell. 2008;14:1111–22.
18. Haschka MD, Soratroi C, Kirschnek S, Hacker G, Hilbe R, Geley S, et al. The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest. Nat Commun. 2015;6:6891.
19. Haschka MD, Karbon G, Soratroi C, O'Neill KL, Luo X, Villunger A. MARCH-BH3-dependent degradation of the MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment. Cell Death Differ. 2020;27:2297–312.
20. Peña-Blanco A, Haschka MD, Jenner A, Zuleger T, Prokais-Cezanne T, Villunger A, et al. Dp1 promotes mitochondrial stress responses to mitotic arrest. Cell Death Differ. 2020;27:2620–34.
21. D’Agostino S, Del Bufo D. Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer. Cells. 2020;9:1287. [https://doi.org/10.3390/cells9051287].
22. Chauhan D, Velankar M, Brahramad M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-xl(XL)-Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374–80.
23. Yecies D, Carlson NE, Deng J, Letal A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304–13.
24. Soares AJ, Leveson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.
25. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24:120–9.
26. Lessene G, Cabotar PE, Sleeks BE, Zobel K, Lowes KN, Adams JM, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013;9:390–7.
27. Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS medicinal Chem Lett. 2014;5:1088–93.
28. Wang L, Doherty GA, Judd AS, Tao ZF, Hansen TM, Frey RR, et al. Discovery of A. 1331852, a first-in-class, potent, and orally-bioavailable BCL-X(L) inhibitor. ACS medicinal Chem Lett. 2020;11:1829–36.
29. Kotschy A, Salvik Z, Murray J, Davidson J, Maragno AL, Le Tourmelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016;538:477–82.
30. Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med. 2017;9:eaam7049. [https://doi.org/10.1126/scitranslmed.aam7049].
31. Graos M, Almeida AD, Chatjerette S. Growth-factor-dependent phosphorylation of Bim in mitosis. Biochem J. 2005;388:185–94.
32. Choi HJ, Zhu BT. Role of cyclin B1/Cdc2 in mediating Bcl-XL phosphorylation and apoptotic cell death following nocodazole-induced mitotic arrest. Mol Cancer. 2013;5:125–37.
33. Upreti M, Galtovskaya EN, Chu R, Tackett AJ, Terrano DT, Granell S, et al. Identification of the major phosphorylation site in Bcl-Xl induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem. 2008;283:35517–25.
34. Deng X, Gao F, Flagg T, May WS Jr. Mono- and multisite phosphorylation enhances Bcl-2’s antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA. 2004;101:153–8.
35. Carpio MA, Michaud M, Zhou W, Fisher JK, Walensky LD, Kats G. BCL-2 family member BOK promotes apoptosis in response to endoplasmic reticulum stress. Proc Natl Acad Sci USA. 2015;112:2301–6.
36. D’Orii B, Engel T, Pfeiffer S, Nandi S, Kaufmann T, Henshall DC, et al. Bok is not pro-apoptotic but suppresses poly ADP-ribose polymerase-dependent cell death pathways and protects against excitotoxic and seizure-induced neuronal injury. J Neurosci. 2016;36:4564–78.
37. Srivastava R, Cao Z, Nedeva C, Naim S, Bachmann D, Rabachini T, et al. BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. Proc Natl Acad Sci USA. 2019;116:15469–74.
38. Rabachini T, Fernandez-Marrero Y, Montani M, Lofrese G, Slayd Y, He Z, et al. BOK promotes chemical-induced hepatocarcinogenesis in mice. Cell Death Differ. 2018;25:708–20.
39. Eom YH, Kim HS, Lee A, Song BJ, Chae BJ. BCL2 as a subtype-specific prognostic marker for breast cancer. J Breast cancer. 2016;19:252–60.
40. Labi V, Erlacher M. How cell death shapes cancer. Cell Death Dis. 2015;6:e1675.
41. Gurova KV, Kwek SS, Koman IE, Komarap AP, Kandel E, Nikiforov MA, et al. Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther. 2002;1:139–44.

42. Slape CI, Saw J, Jovett JB, Aplan PD, Strasser A, Jane SM, et al. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. Blood 2012;120:2475–83.

43. Michalak EM, Vanden Berg CJ, Delbridge AR, Wu L, Scott CL, Adams JM, et al. Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev. 2010;24:1608–13.

44. Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E, Mason SM, et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 2018:9:19.

45. Montero J, Gistalter C, Kim DJ, Sadowitz D, Miles W, Manos M, et al. Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nat Commun. 2019;10:5157.

46. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JJ, et al. Proapoptotic Bak is sequestered by McI and Bcl-xL but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19:1294–305.

47. Tabuchi Y, Matsumoju K, Gonduz M, Imada T, Ono R, Ito M, et al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol. 2009;34:313–9.

48. Flores ML, Castilla C, Ávila R, Ruiz-Borrego M, Sáez C, Japón MA. Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Res Treat. 2012;133:917–28.

49. Miller AV, Hicks MA, Nakajima W, Richardson AC, Windle JJ, Harada H. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor. PLoS ONE. 2013;8:e60885.

50. Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013;24:182–96.

51. Campone M, Noel B, Couriaud C, Grau M, Guillemyn L, Gautier F, et al. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic McI-1. Mol Cancer. 2010;11:110.

52. Bah N, Maillet L, Ryan J, Dubreil S, Gautier F, Letai A, et al. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 2014;5:e1291.

53. Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci USA. 2010;107:12895–905.

54. Goodwin CM, Rossenese OW, Olejniczak ET, Fesik SW. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015;22:2098–106.

55. Lohard S, Bourgeois N, Maillet L, Gautier F, Fétiveau A, Lasla H, et al. STING-dependent paracrine shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nat Commun. 2020;11:259.

56. Eitz Ferrer P, Potthoff S, Kirschnek S, Gasteiger G, Kastenmüller W, Ludwig H, et al. Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa. PLoS Pathog. 2011;7:e1002083.

57. Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279–40.

58. He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020;11:1996.

59. Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, et al. Proteolysis-targeting chimera against BCL-X(L) destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021;12:1281.

60. Willis SN, Fletcher JL, Kaufmann T, van Delft MF, Chen L, Czaborat PE, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007;315:856–9.

61. Topham CH, Taylor SS. Mitosis and apoptosis: how is the balance set? Curr Opin Cell Biol. 2013;25:780–5.

62. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REPorting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–91.

63. Koboldt DC, Fulton RS, McLeod MA, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.

G. Karbon et al.

64. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Chemiack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 2018;173:400–16.e11.

65. Müller HM, Fieg F, Goebel G, Hubalke MM, Widschwendter A, Müller-Holzner E, et al. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer. 2003;89:1934–9.

66. Bléche I, Franc B, Vidaud D, Vidaud M, Lidereau R. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid. 2001;11:147–52.

67. Parson W, Kirchebner R, Mühlmann R, Renner K, Koffer A, Schmidt S, et al. Cancer cell line identification by short tandem repeat profiling: power and limitations. FASEB J. 2005;19:434–6.

68. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–5.

ACKNOWLEDGEMENTS

We are grateful to I. Gagg, C. Soratroi, J. Heppke, I. Gaugg and M. Fleischer for excellent technical assistance, Luca Fava for initiating this line of research in our lab and all current lab members for fruitful discussion. This work was supported by the FWF-funded projects # I-3271 & P29499.

AUTHOR CONTRIBUTIONS

GK performed experiments, analysed data, prepared figures, wrote the manuscript; MH, LRR and CS performed experiments, analysed data; HH performed bioinformatics analyses; WP performed analysis, HF analysed patient samples, prepared related figures, wrote the manuscript, AV analysed data, wrote the manuscript, conceived the study.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-04415-y.

Correspondence and requests for materials should be addressed to Andreas Villunger.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021